Welcome to the “BG Growth Series“, where entrepreneurs tell us about their inspiring stories, share invaluable insights, and offer practical tips to navigate the growth journey. 

In this episode, we feature Abivax, a pioneering biotechnology company at the forefront of developing therapies that harness the body’s natural immune-regulatory mechanisms. Abivax’s work represents a transformative shift in treating chronic inflammatory bowel diseases, offering new hope to patients worldwide. 

We sat down with Abivax’s CEO, Marc de Garidel, and Board Member, Corinna zur Bonsen-Thomas, to gain insights into their commitment to innovation and their vision for the future. Their dedication to advancing medical science is evident in their relentless pursuit of new therapies that address unmet medical needs. 

Abivax is making significant strides in advancing its lead drug candidate, obefazimod, currently in Phase 3 clinical trials for ulcerative colitis. This innovative approach to modulating the immune response holds the potential to revolutionise the management of inflammatory bowel disease and other chronic conditions. 

In its latest phase of growth, Abivax partnered with Bryan, Garnier & Co, which played a pivotal role as the European Lead Manager in their successful USD 236 million Nasdaq IPO. This landmark achievement, the largest ever by a French biotech company, attracted both long-standing shareholders and new specialist investors from Europe and the U.S. 

With a strong foundation in scientific excellence and a clear vision for the future, Abivax is poised to continue making a profound impact on global healthcare. Their journey is a testament to the power of scientific discovery and strategic partnerships. 

Watch this episode of the BG Growth Series to learn more about Abivax’s pioneering work and their commitment to advancing the frontiers of medicine.